title: A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
abstract: OBJECTIVE
  Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study.
  
  
  METHODS
  Women with histologically proven measurable or evaluable epithelial ovarian cancer (any FIGO) who relapsed > or =6 months after discontinuation of first-line, platinum-containing therapy received gemcitabine 1000 mg/m(2) on days 1 and 8 and carboplatin AUC 4 on day 1 (after gemcitabine) every 21 days for up to six cycles.
  
  
  RESULTS
  Of the 40 enrolled/evaluable patients, 6 (15%) had complete response and 19 (47.5%) had partial response (PR), including one patient with PR in nonmeasurable disease (PRNM), for an overall response rate of 62.5% (95% CI, 45.8-77.3%). The median duration of response was 7.8 months (95% CI, 6.7-10.0), the median time to progressive disease was 9.6 months (95% CI, 8.5-11.0), and the median time to treatment failure was 9.3 months (95% CI, 8.2-10.4). The main grade 3/4 toxicities were neutropenia (78% of patients), leukopenia (30%), thrombocytopenia (18%), and anemia (15%); no grade 4 nonhematologic toxicities occurred, and grade 3 nonhematologic toxicities were mild.
  
  
  CONCLUSIONS
  The combination of gemcitabine and carboplatin is active and feasible in platinum-sensitive patients with recurrent ovarian cancer. This regimen is undergoing further evaluation in a large phase III trial.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, SSK Maternity and Women's Health Teaching Hospital, Ankara TR-06100, Turkey. mfkose@celik.net.tr
authors.forename: M F
authors.initials: MF
authors.lastname: Kose
authors.forename: J
authors.initials: J
authors.lastname: Sufliarsky
authors.forename: S
authors.initials: S
authors.lastname: Beslija
authors.forename: P
authors.initials: P
authors.lastname: Saip
authors.forename: G
authors.initials: G
authors.lastname: Tulunay
authors.forename: K
authors.initials: K
authors.lastname: Krejcy
authors.forename: T
authors.initials: T
authors.lastname: Minarik
authors.forename: E
authors.initials: E
authors.lastname: Fitzthum
authors.forename: A
authors.initials: A
authors.lastname: Hayden
authors.forename: A
authors.initials: A
authors.lastname: Melemed
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine